Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism

Core Insights - Veru Inc. is developing enobosarm, a selective androgen receptor modulator (SARM), to address sarcopenic obesity in older adults, particularly those at risk of muscle loss while on GLP-1 receptor agonists for weight loss [3][6][14] - The Phase 2b clinical trial aims to evaluate the safety and efficacy of enobosarm in preserving muscle mass and enhancing fat loss in elderly patients receiving semaglutide (Wegovy®) [14][15] - Enobosarm has a robust safety profile, having been well tolerated in 27 clinical trials with 1581 participants, showing no significant increase in gastrointestinal side effects [4][6] Company Overview - Veru Inc. is a late clinical stage biopharmaceutical company focused on innovative treatments for metabolic diseases, oncology, and ARDS [5][13] - The company is also developing sabizabulin for viral-induced ARDS, pending funding for further trials [8] - Veru has an FDA-approved product, the FC2 Female Condom®, which provides dual protection against unplanned pregnancy and sexually transmitted infections [9] Clinical Development - The Phase 2b trial will involve approximately 150 patients and will measure total lean body mass as the primary endpoint, with secondary endpoints including total body fat mass and physical function [14] - Topline results from the Phase 2b trial are expected by the end of 2024, with an extension study planned to assess muscle maintenance after discontinuation of GLP-1 RA treatment [15]